linvoseltamab for relapsed/refractory multiple myeloma: ims 2023 results with madhav dhodapkar, md
Published 11 months ago • 88 plays • Length 6:17Download video MP4
Download video MP3
Similar videos
-
1:47
linker-mm1: linvoseltamab, a bispecific antibody, in r/r multiple myeloma
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
5:15
linker-mm1: linvoseltamab in patients with r/r multiple myeloma
-
1:47
insights into the efficacy of linvoseltamab in the treatment of r/r multiple myeloma
-
0:45
majestec-2 update: teclistamab plus lenalidomide in r/r multiple myeloma
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
2:24
daratumumab plus vrd for multiple myeloma | nejm
-
6:14
results of iberdomide in combination with dex and daratumumab or bortezomib in patients with rrmm
-
6:07
blood analysis in multiple myeloma
-
1:03:25
the lenalidomide patch for myeloma: what do we know?
-
12:21
elotuzumab and daratumumab in multiple myeloma
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
2:49
trimm-2 update: talquetamab daratumumab in r/r multiple myeloma
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
1:08
long term follow-up results from the phase iii maia trial in myeloma
-
2:26
treating cancer with "bispecific antibodies"
-
3:23
a bright future for multiple myeloma
-
0:55
dr. raptis on drd in newly diagnosed multiple myeloma
-
2:31
stem cell collection in patients with multiple myeloma treated with anti-cd38 monoclonal antibodies
-
1:46
philemon trial: ibrutinib, lenalidomide and rituximab in r/r mcl
-
1:45
dr. fakhri on daratumumab plus vmp in multiple myeloma
-
0:52
mrd for multiple myeloma: is it ready for prime-time?